However, GDC-0449, a Smo inhibitor approved for clinic treatment of advanced BCC [16], failed affect the Gli-luciferase activity caused by either Smo D473H (Figure 5B) or Smo W539L (Figure 5D). Here, GLI1 is linked to skin basal cell carcinoma.